Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Repligen
(NASDAQ:RGEN)
Intraday
$157.48
0
[0.00%]
After-Hours
$157.48
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$157.48
0
[0.00%]
At close: Apr 22
$157.48
0
[0.00%]
PreMarket: 4:20PM EDT
Get Report
Watch
Q1 2024 Earnings in 8 days from now on Wed May 1st, before the market open
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Repligen Stock (NASDAQ:RGEN)
Repligen Stock (NASDAQ: RGEN)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, March 25, 2024
Aehr Test Systems Reports Preliminary Results, Joins Dyne Therapeutics, United Airlines And Other Big Stocks Moving Lower On Monday
Avi Kapoor
-
Mar 25, 2024, 10:32AM
Wednesday, February 21, 2024
What's Going On With Life Science-Focused Repligen Stock Today?
Vandana Singh
-
Feb 21, 2024, 10:25AM
Repligen shares are trading lower after the company issued weak guidance for 2024.
Benzinga Newsdesk
-
Feb 21, 2024, 8:17AM
Repligen Expects Fiscal Year 2024 Adjusted EPS Of $1.42 - $1.49 Versus Consensus Of $1.77
Benzinga Newsdesk
-
Feb 21, 2024, 7:36AM
Repligen Expects Fiscal Year 2024 Revenue Of $620M-$650M Versus Consensus Of $660.68M
Benzinga Newsdesk
-
Feb 21, 2024, 7:36AM
Repligen Q4 Adjusted EPS $0.33, Inline, Sales $155.74M Beat $155.39M Estimate
Benzinga Newsdesk
-
Feb 21, 2024, 7:31AM
Earnings Scheduled For February 21, 2024
Benzinga Insights
-
Feb 21, 2024, 5:09AM
Thursday, February 15, 2024
Keybanc Maintains Overweight on Repligen, Raises Price Target to $220
Benzinga Newsdesk
-
Feb 15, 2024, 2:14PM
Friday, January 26, 2024
Why Intel Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Avi Kapoor
-
Jan 26, 2024, 1:17PM
Booz Allen Hamilton Posts Upbeat Results, Joins AppFolio, Gentex And Other Big Stocks Moving Higher On Friday
Avi Kapoor
-
Jan 26, 2024, 10:30AM
Wednesday, December 20, 2023
Analyst Ratings For Repligen
Benzinga Insights
-
Dec 20, 2023, 4:00PM
JP Morgan Maintains Overweight on Repligen, Raises Price Target to $210
Benzinga Newsdesk
-
Dec 20, 2023, 3:19PM
Thursday, December 07, 2023
Repligen Announces Private Convertible Transaction of $600M Principal Amount of 1.00% Convertible Senior Notes Due 2028 Through Exchange and New Subscription Agreements
Benzinga Newsdesk
-
Dec 7, 2023, 7:31AM
Monday, December 04, 2023
The Latest Analyst Ratings for Repligen
Benzinga Insights
-
Dec 4, 2023, 3:00PM
Benchmark Downgrades Repligen to Hold
Benzinga Newsdesk
-
Dec 4, 2023, 11:28AM
Friday, November 03, 2023
Expedia Group, Gartner, Cloudflare, Cardinal Health And Other Big Stocks Moving Higher On Friday
Lisa Levin
-
Nov 3, 2023, 11:30AM
Thursday, November 02, 2023
Analyst Expectations for Repligen's Future
Benzinga Insights
-
Nov 2, 2023, 12:00PM
Repligen Announced The Commercial Launch Of TangenX SC, The Industry's First Holder-free, Self-contained Tangential Flow Filtration Device
Benzinga Newsdesk
-
Nov 2, 2023, 7:56AM
Wednesday, November 01, 2023
Stifel Maintains Buy on Repligen, Lowers Price Target to $165
Benzinga Newsdesk
-
Nov 1, 2023, 3:38PM
UBS Maintains Buy on Repligen, Lowers Price Target to $170
Benzinga Newsdesk
-
Nov 1, 2023, 3:12PM
Keybanc Maintains Overweight Rating for Repligen: Here's What You Need To Know
Benzinga Insights
-
Nov 1, 2023, 1:00PM
RBC Capital Maintains Outperform on Repligen, Lowers Price Target to $200
Benzinga Newsdesk
-
Nov 1, 2023, 12:52PM
Keybanc Maintains Overweight on Repligen, Lowers Price Target to $210
Benzinga Newsdesk
-
Nov 1, 2023, 5:41AM
Tuesday, October 31, 2023
Why JetBlue Airways Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin
-
Oct 31, 2023, 1:36PM
Repligen shares are trading higher after the company reported better-than-expected Q3 results.
Benzinga Newsdesk
-
Oct 31, 2023, 12:57PM
Repligen's Strong Q3 Recovery: CEO Says Pharma Orders Rebound, Analytics Business Grows
Vandana Singh
-
Oct 31, 2023, 12:32PM
Arista Networks, JinkoSolar, Repligen, Shutterstock And Other Big Stocks Moving Higher On Tuesday
Lisa Levin
-
Oct 31, 2023, 12:04PM
Repligen Expects FY23 Adjusted EPS Of $1.70-$1.76 Versus Prior Guidance Of $1.72-$1.80 And Consensus Of $1.74
Benzinga Newsdesk
-
Oct 31, 2023, 7:38AM
Repligen Expects FY23 Revenues Of $635M-$645M Versus Prior Guidance Of $635M-$665M And Consensus Of $644.53M
Benzinga Newsdesk
-
Oct 31, 2023, 7:38AM
Repligen Q3 Adjusted EPS $0.23 Beats $0.17 Estimate, Sales $141.19M Beat $140.64M Estimate
Benzinga Newsdesk
-
Oct 31, 2023, 7:33AM
Earnings Scheduled For October 31, 2023
Benzinga Insights
-
Oct 31, 2023, 5:44AM
Monday, October 30, 2023
A Preview Of Repligen's Earnings
Benzinga Insights
-
Oct 30, 2023, 5:01PM
Wednesday, October 25, 2023
Shares of healthcare equipment and tools stocks are trading lower in sympathy with Thermo Fisher and Danaher.
Benzinga Newsdesk
-
Oct 25, 2023, 3:03PM
Why Owens Corning Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Lisa Levin
-
Oct 25, 2023, 1:49PM
Tuesday, October 17, 2023
7 Analysts Have This to Say About Repligen
Benzinga Insights
-
Oct 17, 2023, 1:00PM
JP Morgan Maintains Overweight on Repligen, Lowers Price Target to $180
Benzinga Newsdesk
-
Oct 17, 2023, 12:17PM
Monday, October 02, 2023
Repligen Appoints Olivier Loeillot as President, Chief Commercial Officer
Benzinga Newsdesk
-
Oct 2, 2023, 7:36AM
Tuesday, September 26, 2023
Life Sciences Player Repligen's Strategic European Acquisition - What It Means for Investors
Vandana Singh
-
Sep 26, 2023, 3:07PM
Repligen Agrees To Acquire Metenova Expanding Repligen's Fluid Management Portfolio, Complements Single-use Bag Offering, Deal Terms Were Not Disclosed
Benzinga Newsdesk
-
Sep 26, 2023, 7:37AM
Tuesday, September 12, 2023
Repligen Tapped Integer Holdings' Jason K. Garland as CFO, Effective September 25 After Jon K. Snodgres Retired
Benzinga Newsdesk
-
Sep 12, 2023, 7:34AM
Friday, September 08, 2023
RBC Capital Reiterates Outperform on Repligen, Maintains $191 Price Target
Benzinga Newsdesk
-
Sep 8, 2023, 9:10AM
Wednesday, September 06, 2023
What 6 Analyst Ratings Have To Say About Repligen
Benzinga Insights
-
Sep 6, 2023, 12:00PM
RBC Capital Reiterates Outperform on Repligen, Maintains $191 Price Target
Benzinga Newsdesk
-
Sep 6, 2023, 10:08AM
Thursday, August 17, 2023
Sartorius, Repligen Launch Integrated System with Biostat STR And XCell ATF for Upstream Process Intensification
Benzinga Newsdesk
-
Aug 17, 2023, 8:14AM
Thursday, August 03, 2023
Craig-Hallum Maintains Buy on Repligen, Lowers Price Target to $200
Benzinga Newsdesk
-
Aug 3, 2023, 3:26PM
RBC Capital Maintains Outperform on Repligen, Raises Price Target to $195
Benzinga Newsdesk
-
Aug 3, 2023, 10:30AM
Stephens & Co. Maintains Overweight on Repligen, Raises Price Target to $200
Benzinga Newsdesk
-
Aug 3, 2023, 9:07AM
Wednesday, August 02, 2023
Humana, Waters, e.l.f. Beauty, Teva Pharmaceutical And Other Big Stocks Moving Higher On Wednesday
Lisa Levin
-
Aug 2, 2023, 10:36AM
Earnings Scheduled For August 2, 2023
Benzinga Insights
-
Aug 2, 2023, 8:45AM
Repligen Lowers FY23 Revenue Guidance To $635M-$665M Compared To Prior range Of $720M-$760M And Consensus Of $721.07M; Sees Adjusted EPS Of $1.72-$1.80 Compared To Previous Guidance Of $2.35-$2.42 And Consensus Of $2.29
Benzinga Newsdesk
-
Aug 2, 2023, 7:36AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch